Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Cost-effectiveness of a potential vaccine for human papillomavirus.

Publication ,  Journal Article
Sanders, GD; Taira, AV
Published in: Emerg Infect Dis
January 2003

Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor for cervical cancer. Given the substantial disease and death associated with HPV and cervical cancer, development of a prophylactic HPV vaccine is a public health priority. We evaluated the cost-effectiveness of vaccinating adolescent girls for high-risk HPV infections relative to current practice. A vaccine with a 75% probability of immunity against high-risk HPV infection resulted in a life-expectancy gain of 2.8 days or 4.0 quality-adjusted life days at a cost of $246 relative to current practice (incremental cost effectiveness of $22,755/quality-adjusted life year [QALY]). If all 12-year-old girls currently living in the United States were vaccinated, >1,300 deaths from cervical cancer would be averted during their lifetimes. Vaccination of girls against high-risk HPV is relatively cost effective even when vaccine efficacy is low. If the vaccine efficacy rate is 35%, the cost effectiveness increases to $52,398/QALY. Although gains in life expectancy may be modest at the individual level, population benefits are substantial.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Emerg Infect Dis

DOI

ISSN

1080-6040

Publication Date

January 2003

Volume

9

Issue

1

Start / End Page

37 / 48

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccination
  • Uterine Cervical Neoplasms
  • United States
  • Risk Factors
  • Quality-Adjusted Life Years
  • Quality of Life
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • Papillomaviridae
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sanders, G. D., & Taira, A. V. (2003). Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis, 9(1), 37–48. https://doi.org/10.3201/eid0901.020168
Sanders, Gillian D., and Al V. Taira. “Cost-effectiveness of a potential vaccine for human papillomavirus.Emerg Infect Dis 9, no. 1 (January 2003): 37–48. https://doi.org/10.3201/eid0901.020168.
Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003 Jan;9(1):37–48.
Sanders, Gillian D., and Al V. Taira. “Cost-effectiveness of a potential vaccine for human papillomavirus.Emerg Infect Dis, vol. 9, no. 1, Jan. 2003, pp. 37–48. Pubmed, doi:10.3201/eid0901.020168.
Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003 Jan;9(1):37–48.

Published In

Emerg Infect Dis

DOI

ISSN

1080-6040

Publication Date

January 2003

Volume

9

Issue

1

Start / End Page

37 / 48

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccination
  • Uterine Cervical Neoplasms
  • United States
  • Risk Factors
  • Quality-Adjusted Life Years
  • Quality of Life
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • Papillomaviridae